血浆葡萄糖神经酰胺由ATP10D调控且不参与帕金森病发病
研究探讨葡萄糖神经酰胺(GlcCer)升高是否参与帕金森病(PD)发病。采用多种遗传学方法发现,ATP10D而非GBA1是血浆GlcCer水平的主要调控因子,且ATP10D不参与PD发病。血浆GlcCer水平与PD相关但无因果性,不能预测疾病状态。
要点
- ATP10D是血浆GlcCer水平的主要调控因子,而非GBA1。
- ATP10D不参与帕金森病发病。
- 血浆GlcCer与PD相关但无因果性,不能预测疾病状态。
核心结论
- 血浆GlcCer水平由ATP10D主要调控,ATP10D不参与PD发病。
- 血浆GlcCer与PD相关但无因果性,不能预测疾病状态。
- 结果不支持靶向GlcCer治疗GBA1相关PD。
研究设计与样本
- 采用多种遗传学方法研究血浆GlcCer调控及其与PD的关系。
主要发现
- ATP10D而非GBA1是血浆GlcCer水平的主要调控因子。
- ATP10D不参与PD发病。
- 血浆GlcCer水平与PD相关,但无因果性,不能预测疾病状态。
临床怎么用
- 结果不支持靶向GlcCer治疗GBA1相关PD。
- 需探索PD的其他机制和生物标志物。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
GBA1 variants and decreased glucocerebrosidase activity are implicated in Parkinson's disease (PD). We investigated the hypothesis that increased levels of glucosylceramide (GlcCer), a main substrate of glucocerebrosidase, are involved in PD pathogenesis. Using multiple genetic methods, we show that ATPase phospholipid transporting 10D (ATP10D), not GBA1, is the main regulator of plasma GlcCer levels, yet it is not involved in PD pathogenesis. Plasma GlcCer levels were associated with PD, but not in a causative manner, and are not predictive of disease status. These results argue against targeting GlcCer in GBA1-PD, and underscore the need to explore alternative mechanisms and biomarkers for PD. ANN NEUROL 2025;97:873-878.
引用
- Somerville EN, James A, Beetz C, et al. Plasma Glucosylceramide Levels Are Regulated by ATP10D and Are Not Involved in Parkinson's Disease Pathogenesis. Ann Neurol. 2025. PMID: 40022584. doi:10.1002/ana.27219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。